For Healthcare Professionals
Efficacy delivered.
Zero acute serious bacterial infections and high treatment satisfaction.1,2*
See the efficacy data
Protection maintained.
Proven infusion tolerability and steady protection from infection.1-3
See the safety data
Efficacy delivered.
Zero acute serious bacterial infections and high treatment satisfaction.1,2*
See the efficacy dataProtection maintained.
Proven infusion tolerability and steady protection from infection.1-3
See the safety data*The efficacy of QIVIGY was evaluated in an open-label, prospective clinical study in adult patients with primary humoral immunodeficiency. A total of 47 patients received intravenous infusions of QIVIGY at a dose of 266 mg/kg to 826 mg/kg on a 4-week (n=39) or a 3-week (n=8) infusion cycle for 12 months. There are no comparative head-to-head trials with QIVIGY.1,2
IVIG, intravenous immune globulin; PI, primary immunodeficiency.
INDICATIONS AND USAGE
QIVIGY® (immune globulin intravenous, human-kthm) is a 10% immune globulin (Ig) liquid indicated for the treatment of adults with primary humoral immunodeficiency.
Important safety information
WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE
See full prescribing information for complete boxed warning.
- Thrombosis may occur with immune globulin products, including QIVIGY.
- Renal dysfunction, acute renal failure, osmotic nephrosis may occur with immune globulin intravenous (IGIV) products in predisposed patients. Such events require immediate medical intervention, if not recognized or managed appropriately, may result in persistent or significant disability or incapacity or lead to fatal outcome.
- For patients at risk of thrombosis, renal dysfunction or failure, administer QIVIGY at the minimum dose available and the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
CONTRAINDICATIONS
QIVIGY is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA deficient patients with antibodies against IgA and history of hypersensitivity.
WARNINGS AND PRECAUTIONS
Severe hypersensitivity reactions, including anaphylaxis, may occur. In case of hypersensitivity, discontinue QIVIGY infusion and manage as appropriate.
Hyperproteinemia, hyperviscosity, and hyponatremia may occur in patients receiving IGIV treatment, including QIVIGY.
Aseptic meningitis syndrome may occur in patients receiving IGIV treatment, especially with high doses or rapid infusion.
Hemolysis can develop subsequent to IGIV treatment. Monitor patients for hemolysis.
Transfusion-related acute lung injury: Monitor patients for pulmonary adverse reactions.
Transmissible infectious agents: QIVIGY is made from human plasma and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Interference with laboratory tests: After infusion of Ig, transitory rise of passively transferred antibodies may yield positive serological results, with potential for misleading interpretation.
ADVERSE REACTIONS
The most common adverse reactions occurring in ≥5% of patients treated were headache, fatigue, infusion-related reaction, Coombs direct test positive, nausea, sinusitis, dizziness, and diarrhea.
To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-3KDRION (1-855-353-7466) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information for complete prescribing details, including Boxed Warning.
References: 1. QIVIGY [prescribing information]. Kedrion Biopharma Inc.; 2025. 2. Data on file. REF-01262. Kedrion Biopharma Inc.; 2024. 3. Data on file. REF-01273. Kedrion Biopharma Inc.; 2025.